+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Company Analysis: Seagen

  • ID: 5357319
  • Company Profile
  • January 2021
  • 48 pages
  • Datamonitor Healthcare
The publisher explores Seagen’s prescription pharmaceutical performance and outlook over 2019-29.

Snapshot
  • Overview - Seagen is poised for continued growth.
  • Key themes - [1] Adcetris growth is slowing due to increasing market penetration and inroads from competing products like Keytruda [2] Launch of Padcev and Tukysa will drive further growth in 2020 and beyond [3] Collaborative licensing agreements with large pharmaceutical companies provide diversified sources of revenue.
Model updates (4 November 2020)
  • Adcetris forecast adjusted lower due to sales trends
  • Padcev forecast adjusted higher due to recent data in MIBC and long-term guidance given by Astellas
  • Tukysa forecast adjusted higher due to launch trends.
Model updates (31 July 2020)
  • Padcev forecast adjusted higher due to continued strong launch trends
  • Tukysa forecast adjusted higher due to strong initial launch
  • Tisotumab vedotin forecast added after results of innovaTV 204 trial.
Model updates (30 April 2020)
  • Padcev forecast adjusted higher due to strong initial launch
  • Tucatinib name changed to Tukysa; forecast adjusted higher due to earlier-than-expected approval.
Model updates (6 February 2020)
Note: Product cover images may vary from those shown
Company Background
  • Company Overview
  • Key Metrics
  • SWOT Analysis
  • Key Drug & Company Information
  • Company Comparison
Recent Earnings Review
  • Earnings Overview
  • Notable Quotes & Important Topics
  • Pharma Insights Analysis
Company Forecast
  • Prescription Pharmaceuticals Sales Outlook
  • Branded Drug Outlook
  • Launch Profile Outlook
  • Therapy Area Outlook
  • Regional Sales Outlook
  • Lifecycle Analysis
Company Profile
  • Marketed & Pipeline Drugs
  • Recent Events & Analyst Opinions
  • Upcoming Catalysts
  • Recent Insights
Clinical Trial Overview
  • Clinical Trial Snapshot
  • Clinical Trials by Country
  • Clinical Trials by Status and Phase
  • Clinical Trials by Drug
Note: Product cover images may vary from those shown
Adroll
adroll